Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · IEX Real-Time Price · USD
59.85
+2.75 (4.82%)
May 3, 2024, 1:24 PM EDT - Market open
Keros Therapeutics Revenue
In the year 2023, Keros Therapeutics had annual revenue of $151.00K. Revenue in the quarter ending December 31, 2023 was $143.00K.
Revenue (ttm)
$151.00K
Revenue Growth
n/a
P/S Ratio
13,606.67
Revenue / Employee
$1,110
Employees
136
Market Cap
2.16B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 151.00K | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 20.10M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 10.00M | - | - |
Dec 31, 2018 | 10.00M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CONMED | 1.26B |
Amphastar Pharmaceuticals | 644.40M |
Deciphera Pharmaceuticals | 163.36M |
RxSight | 89.08M |
Kymera Therapeutics | 78.59M |
Intellia Therapeutics | 36.28M |
NewAmsterdam Pharma Company | 15.66M |
KROS News
- 2 months ago - Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference - GlobeNewsWire
- 2 months ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 3 months ago - Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Keros Therapeutics to Develop KER-065 for the Treatment of Obesity - GlobeNewsWire
- 5 months ago - Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire